분자 모델링 소프트웨어 시장 : 세계 예측(2026-2032년)

The Molecular Modelling Software Market is projected to grow by USD 2.55 billion at a CAGR of 12.73% by 2032.

Molecular Modelling Software: Executive Summary and Strategic Context

Molecular modelling software supports the representation, simulation, and analysis of molecular systems across pharmaceutical research, materials development, biotechnology, chemicals, and academic science. Its value lies in helping researchers investigate molecular structure, interactions, energetics, dynamics, and properties before committing to laboratory work. Adoption is shaped by computational capability, data quality, workflow integration, reproducibility requirements, licensing models, and the availability of trained scientific users.

Workflow Integration and Open Science Are Reshaping Molecular Modelling

The landscape is shifting from isolated modelling tools toward connected research workflows that combine structure preparation, simulation, visualization, data management, and experimental validation. Cloud and high-performance computing are expanding access to computationally intensive methods, while open-source ecosystems are encouraging customization and reproducible research. Interoperability with electronic laboratory systems, scientific databases, automation platforms, and laboratory instruments is becoming increasingly important. Users also place greater emphasis on transparent parameterization, version control, auditability, and validation against experimental evidence.

Artificial Intelligence Is Accelerating Prediction, Screening, and Model Selection

Artificial intelligence is influencing molecular modelling through machine-learning potentials, property prediction, virtual screening, generative design, surrogate models, and automated analysis of simulation data. These methods can reduce computational cost and help prioritize experiments, but their usefulness depends on representative training data, sound validation, uncertainty quantification, and domain expertise. Hybrid workflows that combine physics-based modelling with data-driven methods are particularly relevant where interpretability, transferability, and scientific constraints matter. Leaders should treat AI as an augmentation layer rather than a substitute for experimental confirmation or rigorous molecular theory.

Regional Insights: Capability, Infrastructure, and Regulation Shape Adoption

North America benefits from strong research institutions, advanced computing infrastructure, and close links among pharmaceutical, biotechnology, technology, and academic organizations. Europe emphasizes collaborative research, open science, data governance, and computational sustainability, with the European Union supporting cross-border scientific programs and standards-oriented practices. Asia-Pacific combines expanding research capacity with substantial activity in pharmaceuticals, chemicals, materials, and electronics, while adoption varies according to infrastructure and skills availability. Latin America is developing modelling capability through universities, public laboratories, and industrial research, with affordability and access to specialized expertise remaining important considerations. The Middle East is investing selectively in advanced research infrastructure and innovation programs, while Africa shows emerging potential through academic and public-sector initiatives, although access to computing, funding, and specialized training remains uneven.

Group Insights: Collaborative Blocs Influence Standards, Skills, and Compute Access

ASEAN provides a setting for expanding scientific collaboration and digital research capacity, with adoption influenced by differences in infrastructure and technical skills among member economies. BRICS members contribute diverse strengths in computational science, higher education, pharmaceuticals, chemicals, and materials research, while collaboration may be affected by differing regulatory and data environments. The European Union places strong emphasis on research coordination, privacy, interoperability, and responsible data use. G7 economies generally combine mature scientific ecosystems with advanced computing and industrial demand. GCC countries are building high-performance research capabilities and attracting specialized scientific activity, while NATO members share interests in resilient digital infrastructure, secure collaboration, and advanced materials and life-science research.

Country Insights: National Research Priorities Create Distinct Adoption Patterns

The United States and Canada combine deep academic expertise, industrial research, and access to advanced computing. The United Kingdom, Germany, France, Italy, and Spain support broad university and industrial modelling communities, with emphasis on pharmaceutical research, materials, chemicals, and collaborative science. China, Japan, South Korea, and India have substantial activity across electronics, materials, chemicals, biotechnology, and drug discovery, supported by expanding computational and scientific infrastructure. Australia contributes through university-led research, mining and materials science, biotechnology, and public research programs. Brazil and Mexico are strengthening modelling applications in pharmaceuticals, chemicals, agriculture-related science, and academia. Russia retains capabilities in theoretical and computational science, although access to international collaboration, software, and infrastructure can affect research workflows.

Actionable Priorities for Leaders Building Scalable Modelling Workflows

Industry leaders should first define priority scientific decisions and select methods according to validation needs rather than novelty alone. They should build interoperable workflows with governed molecular data, documented parameters, reproducible environments, and clear links between computational outputs and laboratory results. Investment in scalable computing should be paired with cost controls, workload monitoring, and access policies for researchers. AI initiatives should include curated datasets, external validation, uncertainty reporting, bias checks, and human review. Organizations should also develop multidisciplinary talent by combining computational chemistry, software engineering, statistics, domain science, and laboratory expertise. Finally, partnerships with universities, public research organizations, and standards communities can improve skills, interoperability, and responsible adoption.

Research Methodology: Evidence-Based Assessment of the Software Landscape

This executive summary uses the defined market scope of molecular modelling software and organizes evidence around technology evolution, research workflows, artificial intelligence, geography, economic groupings, and national capabilities. The assessment considers publicly documented scientific practices, computational research trends, infrastructure conditions, regulatory themes, and application requirements across pharmaceuticals, biotechnology, chemicals, materials, and academia. Insights are qualitative and comparative; they do not represent market estimates, market shares, forecasts, or financial sizing. Regional, group, and country observations reflect differences in research capacity, industrial composition, policy environment, computing access, collaboration patterns, and specialist skills.

Conclusion: Competitive Advantage Will Depend on Trusted, Connected Computation

Molecular modelling software is becoming more valuable when embedded in reproducible, interoperable, and experimentally connected research systems. AI is broadening the range of feasible predictions and accelerating prioritization, but reliable outcomes still depend on scientific validation, quality data, and expert oversight. Regional and national differences in infrastructure, skills, regulation, and collaboration will continue to shape implementation. Organizations that combine rigorous modelling practices with scalable computing, responsible AI, and strong laboratory integration will be best positioned to convert computational insight into practical scientific progress.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Molecular Modelling Software Market, by Model Type

• 7.1. Introduction
• 7.2. Hybrid Qm/Mm
• 7.3. Molecular Mechanics
• 7.4. Quantum Mechanics

8. Molecular Modelling Software Market, by Pricing Model

• 8.1. Introduction
• 8.2. Freemium
• 8.3. Pay As You Go
• 8.4. Perpetual License
• 8.5. Subscription
  • 8.5.1. Annual Subscription
  • 8.5.2. Monthly Subscription

9. Molecular Modelling Software Market, by Deployment Mode

• 9.1. Introduction
• 9.2. Cloud
  • 9.2.1. Hybrid Cloud
  • 9.2.2. Private Cloud
  • 9.2.3. Public Cloud
• 9.3. On-Premise

10. Molecular Modelling Software Market, by Application

• 10.1. Introduction
• 10.2. Chemical Reaction Analysis
• 10.3. Drug Discovery
• 10.4. Education
• 10.5. Material Science
• 10.6. Protein Modeling

11. Molecular Modelling Software Market, by End User

• 11.1. Introduction
• 11.2. Academic Research
• 11.3. Biotechnology
• 11.4. Chemical Industry
• 11.5. Cosmetics
• 11.6. Pharmaceuticals

12. Molecular Modelling Software Market, by Region

• 12.1. Introduction
• 12.2. Asia-Pacific
• 12.3. North America
• 12.4. Latin America
• 12.5. Europe
• 12.6. Middle East
• 12.7. Africa

13. Molecular Modelling Software Market, by Group

• 13.1. Introduction
• 13.2. ASEAN
• 13.3. GCC
• 13.4. European Union
• 13.5. BRICS
• 13.6. G7
• 13.7. NATO

14. Molecular Modelling Software Market, by Country

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. United Kingdom
• 14.7. Germany
• 14.8. France
• 14.9. Russia
• 14.10. Italy
• 14.11. Spain
• 14.12. China
• 14.13. India
• 14.14. Japan
• 14.15. Australia
• 14.16. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. Market Concentration Analysis, 2025
  • 15.2.1. Concentration Ratio (CR)
  • 15.2.2. Herfindahl Hirschman Index (HHI)
• 15.3. Recent Developments & Impact Analysis, 2025
• 15.4. Product Portfolio Analysis, 2025
• 15.5. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Accelrys, Inc.
• 16.2. Acorn Technology, Inc.
• 16.3. AMBER Molecular Simulation Software Consortium
• 16.4. Certara, Inc.
• 16.5. ChemAxon Ltd.
• 16.6. Chemical Computing Group ULC
• 16.7. Cresset Group Ltd.
• 16.8. Dassault Systemes SE
• 16.9. InterBioScreen Ltd.
• 16.10. Molecular Discovery Systems Ltd.
• 16.11. MolSoft LLC
• 16.12. Nanome, Inc.
• 16.13. OpenEye Scientific Software, Inc.
• 16.14. Schrodinger, Inc.
• 16.15. Simulations Plus, Inc.

17. Key Experts